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Abstract 
 
The reliability of complete blood counts (CBC) obtained by LaserCyte® were evaluated in 41 dogs affected by malignant 
lymphoma (29 cases), leukemia (8 cases) and miscellaneous blood disorders (4 cases). A total of 89 CBCs were performed. 
Different degrees of anemia, leukocytosis, leucopenia and thrombocytopenia or thrombocytosis were detected. Results 
provided from LaserCyte® were compared with those from HeCo VET C
® impedance cell counter, manual leukocyte 
differential counts and reticulocyte counts by the regression coefficient (r). The LaserCyte® cell counter provides reliable 
results for diagnosing and monitoring onco-hematological disorders, in part due to the provision of alarm codes that indicate 
when a review of the stained blood smear is necessary. The only unreliable CBC parameter was eosinophil count. 
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ةنطرسم ةيومد تابارطضا تاوذ بلاكلا يف مدلا تانوكم دعل تياسرزيل مادختسإ  
  
يجرويج مإ و يجويلوك يب ،يتزيب مإ ،يراكم يد ،سابول يج ،ازافك يأ  
  
ايلاطيا ،ازيب ةعماج ،ةيرطيبلا ةيريرسلا مولعلا مسق  
  
ةصلاخلا   
 
 مييقت ىرج تانوكم دع لماكلا مدلا   تياسرزيل زاھجب  ® LaserCyte يف     ٤١   نم يناعت ابلك ً  ةثيبخلا ةيوافميللا ددغلا رثأت  ) ٢٩ ةلاح  (  ،
 مدلا ناطرسو ) ٨ تلااح   (  مدلا تابارطضاو لا  ةعونتم ) ٤ تلااح   .(  هعومجم ام ذيفنت مت ٨٩ و ،اصحف  ً  رقف نم ةفلتخم تاجرد نع فشكلا مت
ضيبلا تايركلا ددع ةدايزو ،مدلا و  صقن اھ    صقن نع لاضف ً تاحيفصلا  ةيومدلا  وأ   رثك اھت  .  كلت عم جئاتنلا ةنراقم تمتو  صحف نم ةجتانلا
وكيھ   ® VETC    يوديلا دعلاو   ب رادحنلاا لماعم  .  مدقي تياسرزيللا نأب ظحولو  تابارطضا دصرو صيخشتل ةقوثوم جئاتن لا بلاك ةيومدلا   
ةنطرسملا شت يتلا هيبنتلا زومر ريفوت ىلإ ايئزج كلذ عجريو ، ا  دنع ر تاحسملا صحف ةيومدلا   . و ناك  صحفلا   دامتعلاا نكميلا يذلا ديحولا
ةضمحلا تايركلا دع وھ ةيلع .  
 
 
Introduction  
 
In veterinary clinical practice it is important to have a 
cell counter that provides convenient, rapid and reliable 
complete blood counts (CBC), even during severe 
hematolological derangements (1). In several 
oncohematological diseases, as lymphomas and leukemia, 
drastic alteration of the CBC are observed (anemia, 
leukocytosis, leucopenia, thrombocytopenia and 
thrombocytosis). The increasing availability of more 
sophisticated instruments means that they should be 
accessible, even to a practitioner working in small to 
medium size facilities (2). LaserCyte® is a laser cell 
counter that measures 24 hematological parameters 
including reticulocytes, important markers of degree of 
regeneration in cases of anemia, and the complete 
differential leukocyte count (1-3).  Iraqi Journal of Veterinary Sciences, Vol. 27, No. 1, 2013 (1-7) 
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The goal of this study was to evaluate reliability of the 
hematological results supplied by LaserCyte® for dogs 
with previously diagnosed oncohematological disorders 
(4,5). These findings were compared with results obtained 
from an impedance cell counter (HeCo VET C
®), and from 
manual counts of both the leukocyte partition and 
reticulocytes.  
 
Materials and methods 
 
Patient selection 
Forty-one dogs of various breed, gender, and age were 
included in the described study (Tables 1, 2). These dogs 
had been diagnosed with several different hematological 
disorders, including malignant lymphoma (ML) (n= 29), 
leukemia (LEUK) (n= 8) and other miscellaneous blood 
disorders (MBD) (n= 4). Most of these patients were 
repeatedly tested over the time period resulting in 89 CBCs 
in total. Full information on signalment and diagnosis is 
reported in Table 2.  
The diagnosis was formulated based on complete 
physical examination and the interpretation of several 
laboratory investigations including CBC, serum 
biochemical profile, urinalysis, serum protein 
electrophoresis, Leishmania infantum and Ehrlichia canis 
serology, lymph-node and bone marrow cytopathological 
evaluation, immunophenotyping on cell retrieved from 
lymph node, bone marrow or peripheral blood, and 
diagnostic imaging (abdominal ultrasound and/or thoracic 
and/or abdominal radiology) (6-8).
  The blood collected 
from the jugular vein or, alternatively, from the cephalic 
vein was split in two tubes with K3EDTA as anticoagulant. 
One tube was analyzed by HeCoVet C
® cell counter, and 
the other by Lasercyte
®. All the blood samples were 
analyzed within one hour of the collection. 
 
Table 1: List of malignant lymphoma cases in dogs. 
 
Case number (breed, gender, year)  Cytological 
diagnosis 
Immuno-
phenotype  Clinical diagnosis  CBCs 
(n) 
1-8 (Mixed, f 9y; Bullmastiff, m 5y; Labrador, f 
5y; Argentine Dogo, f 6y; Shitzu, m 9y; Labrador, 
m 5y; Mixed, m 8y; German shepherd, m 9y) 
Centroblastic 
polymorphic  B-cell  Multicentric lymphoma, 
stage III  15 
9 (German shepherd, f 9y)  Small cell    7 
10 (Boxer, m 9y)  Lymphoplasmocitic  T-cell   2 
11-15 (Mixed, m 5y; Rottweiler, f 9y; German 
shepherd, m 7y; Corso, f 8y; Mixed, m 6y) 
Centroblastic 
polymorphic 
Multicentric lymphoma, 
stage IV  13 
16-17 (Dobermann, m 5y; German shepherd, m 
5y)  Immunoblastic 
B-cell 
 10 
18 (Dobermann, f 10y)  Lymphoblastic  nd    3 
19-22 (Collie, m 11y; Bulldog, m 6y; Mixed, f 
5y; German shepherd, m 13y) 
Centroblastic 
polymorphic  B-cell  Multicentric lymphoma, 
stage Va  4 
23 (Boxer, f 10y)  Mixed Pleomorphic  T-cell    1 
24 (Mixed, f 8y)    nd  Intestinal lymphoma, 
stage IV  1 
25 (Boxer, m 7y)  Mixed Pleomorphic  Mediastinal lymphoma  1 
26 (Mixed, m 9y)  Lymphocitic    1 
27 (Golden Retriever, m 8y)  Lymphoblastic 
T-cell 
 5 
28 (Dobermann, m 10y)  Macronucleated 
medium size cell  nd  Multicentric lymphoma, 
stage Vb  1 
29 (Golden Retriever, f 4y)  Immunoblastic  T-cell    1 
Legend: f, female; m, male; nd, not determined; n, number; y, year; romanic numbers represent clinical stage of lymphoma. 
 
LaserCyte® cell-counter 
LaserCyte
® Hematology Analyzer (IDEXX, 
Laboratories Inc., Westbrook, ME, USA) is a laser cell 
counter that measures 24 hematological parameters: total 
erythrocyte count (RBC), hematocrit (HCT), hemoglobin 
(HGB), mean corpuscular volume (MCV), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration 
(MCHC), red cell dimension width (RDW), reticulocytes 
(RETIC both percentage [%] and absolute value [av]), total 
leukocyte count (WBC), neutrophils count (NEU, both % 
and av), lymphocytes (LYM, both % and av), monocytes Iraqi Journal of Veterinary Sciences, Vol. 27, No. 1, 2013 (1-7) 
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(MONO, eosinophils (EOS, both % and av), basophils 
(BAS, both % and av), platelet (PLT), mean platelet 
volume (MPV), platelcrit (PCT) and platelet dimension 
width (PDW). Both parameters are reported as absolute or 
percentage values within about ten minutes of the analysis 
commencing (using the 1.84 version software) (1,2,9).
 
LaserCyte
® requires 95 µl of anticoagulated blood 
collected in the VetCollect™ lavender top tube. This is 
mixed with a special solution containing new Methylene 
blue dye, a reagent that cause the erythrocytes to became 
spherical, and qualiBeads®, this mixture is provided in a 
tube, CBC5R. The LaserCyte
® has 33 different 'alarm 
codes' that appear on the result data sheet if there has been a 
problem during sample analysis. These codes query the 
validity of one or more of the values obtained. Moreover, 
they instruct the operator to carry out trouble shooting 
investigations (2,9). 
 
Table 2: Cases of leukemia and miscellaneous blood disorders. 
 
Case number (breed, gender, year)  Clinical and cytological diagnosis  CBCs (n)  
Leukemia 
30-31(Golden Retriever, f 4y; Mixed, f 9y)  Acute lymphoblastic leukemia  2 
32-34 (Mixed, m 5y; German shepherd, f 6y; English 
Setter, m 9y)  Acute myeloid leukemia   3 
35 (Mixed, f 3y)  Acute myelomonocitic leukemia  1 
36 (Pomeranian, m 11y)  Chronic lymphatic leukemia  1 
37 (Mixed, f 12y)  Essential thrombocytemia  6 
Miscellaneous blood disorders 
38 (Labrador, m 12y)  Multiple myeloma   3 
39 (Rottweiler, f 9y)  Paraneoplastic syndrome from an oral carcinoma  2 
40 (Weimarainer, m 12y)  Paraneoplastic syndrome of unknown origin   4 
41 (Mixed, m 10y)  Leukemoid reaction from gastrointestinal 
neoplasia  1 
Legend: f, female; m, male; n, number; y, year. 
 
Comparative instrumentation or procedure 
For comparative purposes an electric impedance cell-
counter HeCo VET C
® (SEAC, Calenzano, Firenze, Italy) 
was used. This device does not measure leukocyte 
differential or reticulocyte count however, these were 
obtained through manual methods. The HeCo VET C
® 
measures RBCs, WBCs, PLTs, MCV, and MPV directly by 
means of impedance principle. Subsequent calculations 
provide MCH, MCHC, RDW and PDW. HGB is measured 
directly by means of photometric method, using a solid 
sensor with a 546 nm filter (10,11). 
The manual leukocyte differential count was performed 
on a thin peripheral blood smear, prepared within one hour 
of blood collection and stained with Diff-Quik
® (Medion 
Diagnostics GmbH, Dudingen, Switzerland). Using a light 
microscope, at least 100 WBCs were subdivided into five 
populations (NEU, LYM, MONO, and EOS) by two 
different experienced operators. The BASO count was not 
performed as the stain technique used does not adequately 
identify dog basophils. Reticulocyte count was performed 
using the new methylene blue technique and by counting at 
least 1,000 RBCs. Only samples with a HCT of less than 
30% were evaluated by this method, there were 28 samples 
fitting this criteria. The entire procedure for comparison is 
similar to that reported in previous papers (3,12-19). 
 
Statistical analyses 
In order to compare results obtained from LaserCyte
® 
and the adopted comparative methods, a linear regression 
study was performed (Excel®, Microsoft). The regression 
line, its equation, the resulting regression coefficient (r) 
values and the calculated P value were considered (20,21-
25). 
The (r) value estimates the concordance between two 
methods, it is considered optimal within the range 1-0.9, 
fair between 0.89-0.75, acceptable between 0.74-0.5 and 
inadequate when < 0.5 (10,16,17,19). 
Both the full (with and without considering the alarm) 
results and results without considering the alarm were 
compared with the results obtained using HeCo VET C®.  
 
Results 
 
The (r) values for all the samples obtained both before 
and after considering the alarm codes flagged by 
LaserCyte® are reported in Table 3.  
It is noteworthy that 57 out of 89 CBCs showed several 
degrees of anemia and 34 out of 89 and 25 out of 89 
showed leukocytosis and leucopenia, respectively.  
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Table 3: Regression coefficient (r) measured for all the CBCs. 
 
Results irrespective of alarm codes   Results considering alarm codes  Parameter 
CBCs (n)  (r)   evaluation  CBCs (n)  (r) evaluation 
RBC  89  0.95 **  Optimal  88  0.95 **  Optimal 
HCT  89  0.94 **  Optimal  88  0.94 **  Optimal 
HGB  88  0.97 **  Optimal  72  0.97 **  Optimal 
MCV  89  0.77 **  Fair  88  0.77 **  Fair 
MCH  89  0.37 *  Inadequate  88  0.37 *  Inadequate 
MCHC  64  0.14 ns  Inadequate  64  0.14 ns  Inadequate 
RDW  89  0.85 **  Fair  88  0.83 **  Fair 
% RETIC  28  0.81 **  Fair  28  0.81 **  Fair 
RETIC 28  0.74  **  Acceptable 28  0.74  **  Acceptable 
WBC  88  0.98 **  Optimal  71  0.97 **  Optimal 
NEU  88  0.32 *  Inadequate  59  0.97 **  Optimal 
LYM 88  0.67  **  Acceptable 58  0.90  **  Optimal 
MONO 88  0.24  *  Acceptable 51  0.81  ** Fair 
EOS  88  0.03 ns  Inadequate  66  0.19 ns  Inadequate 
PLT  89  0.97 **  Optimal  82  0.92 **  Optimal 
MPV 87  0.55  **  Acceptable 80  0.58  **  Acceptable 
Legend: **, P< 0.01; * P< 0.05; ns, not significant. 
 
In the described study, some parameters (mostly MCHC, 
occasionally HGB, WBC, NEU, LYM, MONO, EOS, and 
MPV) were not considered because LaserCyte® software 
did not provide results when these values were out of 
acceptable ranges. 
CBC results, irrespective of whether or not the alarm 
was triggered gave optimal (r) values for RBC, HCT, HGB, 
WBC, and PLT, fair values for MCV, RDW, and % RETIC, 
acceptable values for RETIC, LYM, MONO and MPV, but 
inadequate values for MCH, MCHC, NEU, and EOS. Using 
flagged values or values detected with alarm codes (r) only 
improved consistency for NEU (from inadequate to 
optimal), LYM (from acceptable to optimal), and MONO 
(from acceptable to fair). In contrast, the (r) value did not 
improve for the other parameters. 
65 CBCs from ML patients were examined, however 
some parameters (mostly MCHC, occasionally HGB, WBC, 
NEU, LYM, MONO, and EOS) were not measured for the 
reasons stated above. The (r) value was optimal for RBC, 
HCT, HGB, WBC, and PLT, fair for RDW and NEU, and 
finally acceptable for MCV, % RETIC, RETIC, MONO, 
and MPV, it was inadequate for MCH, MCHC, and EOS 
however. 
Thirteen CBCs from LEUK patients were examined. 
The (r) was optimal for RBC, HCT, WBC, NEU, and MPV, 
fair for HGB, MCV, and LYM, acceptable for MCHC and 
MONO, RDW and % RETIC, but inadequate for MCH, 
RETIC, EOS, and PLT. Some parameters could not be 
evaluated due to the small sample size. 
Ten CBCs from MBD patients were examined. The (r) 
was optimal for RBC, HCT, HGB, RDW, % RETIC, 
RETIC, WBC, NEU, MONO, and PLT, fair for MCV, and 
MCH, acceptable for LYM and EOS, but inadequate for 
MCHC and PLT. 
The (r) obtained considering the alarm codes and 
subdividing the patients based on their disorder are reported 
in Table 4.  
The significance of alarm codes occurring in this study 
is reported in Table 5. 
The occurrence of alarm codes from the CBCs obtained 
from LaserCyte® in all patients and in patients subdivided 
by disorders is reported in Table 6. The most frequently 
recorded alarms were the HI 1 and RB 9, followed by DB 
1/2 and DB 1/3. 
 
Discussion 
 
The LaserCyte® and associated software considerably 
aid the practitioner in evaluating patient CBCs. Indeed, 
even if there is severe hematological derangement, the 
instrument has alarms that guide interpretation of results. 
Specifically, there was optimal concordance between 
the LaserCyte® and HeCo VET C® for RBC, HCT and 
HGB. Hence, LaserCyte® can correctly identify anemia 
regardless of severity, as previously documented in other 
papers (5,17). 
The concordance between the two instruments for MCV 
was always fair except in the lymphoma cases where the (r) 
decreased to 0.71. In contrast, MCH and MCHC produced 
inadequate values, because these parameters are computed 
and not measured. 
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Table 4: Regression coefficient (r) measured for the different disorder groups (after considering the alarm codes from 
LaserCyte®). 
 
Lymphoma patients  Leukemia patients  Miscellaneous blood disorder patients
Parameter  n° of 
CBCs  (r)   evaluation  n° of 
CBCs  (r)   evaluation  n° of 
CBCs  (r) evaluation 
RBC  65  0.95 **  Optimal  13  0.96 **  Optimal  10  0.97 **  Optimal 
HCT  65  0.92 **  Optimal  13  0.95 **  Optimal  10  0.94 **  Optimal 
HGB  53  0.98 **  Optimal  12  0.88 **  Fair  7  0.95 **  Optimal 
MCV 65  0.71  **  Acceptable  13  0.79 **  Fair  10  0.81 **  Fair 
MCH  65  0.47 **  Inadequate  13  0.07 ns  Inadequate  10  0.77 **  Fair 
MCHC 45  0.03  ns  Inadequate 10  0.51  ns Acceptable 9 0.16  ns  Inadequate 
RDW 65  0.80  **  Fair  13 0.67  **  Acceptable  10 0.95  **  Optimal 
% RETIC  14  0.63 *  Acceptable  11  0.64 *  Acceptable  3  1.00 **  Optimal 
RETIC 14  0.64  **  Acceptable 11  0.24  ns Inadequate 3  1.00  **  Optimal 
WBC  53  0.99 **  Optimal  11  0.96 **  Optimal  7  1.00 **  Optimal 
NEU  46  0.81 **  Fair  6  0.99 **  Optimal  7  0.99 **  Optimal 
LYM 44  0.91  **  Optimal  7  0.87  ns Fair  7  0.54  ns  Acceptable 
MONO 39  0.62  **  Acceptable  5  0.60  ns Acceptable  7  1.00  **  Optimal 
EOS 51  0.01  ns  Inadequate 8  0.16  ns  Inadequate 7  0.60  ns Acceptable 
PLT  65  0.93 **  Optimal  7  0.23 ns  Inadequate  10  0.97 **  Optimal 
MPV 65  0.62  **  Acceptable  5  0.92  * Optimal 10  0.40  ns  Inadequate 
Legend: **, P< 0.01; * P< 0.05; ns, not significant; nd, not determined. 
 
Table 5: Significance of alarm codes of Lasercyte® occurred in this study. 
 
Code  Full text  Flagged Parameters   Type of 
message
1  Explanation Troubleshooting 
HI 1  HGB sheath 
timing  HGB   (a)  Issue reading the HGB 
reference solution.   Confirm the HGB results 
PB 1 
PLT out of 
reportable 
range 
PLT reported as 
either <1 K/μL or 
>2500K/μL 
(b) 
If the PLT value is <1 
K/μL, the MPV, PDW 
and PCT are not 
reported and PLT is less 
than 1 K/μL 
If the PLT value is >2500 K/μL, 
Evaluate the patient’s condition; 
if a very high or low PLT value is 
not expected, rerun sample or 
evaluate blood film 
RB 1  Too many 
RBC fragments 
RBC, HCT, MCH, 
MCHC, RETIC, 
%RETIC, PLT, MPV, 
PDW, PCT  
(b) 
Fragile RBCs may 
interfere with the PLT 
and RBC counts 
Confirm the PLT value with a 
blood film 
RB 3 
Low PLT 
statistics. 
Distribution 
parameter not 
reported 
MPV, PDW, PCT – 
no results reported  (b) 
The PLT count was less 
than 25 K/μL 
Evaluate the patient’s condition; 
if a very high or low PLT value is 
not expected, rerun the sample or 
evaluate the blood film 
RB 9 
MCHC out of 
reportable 
range 
MCHC – no results 
reported. RBC, HCT, 
PLT, PCT, MCV, MPV
(b) 
The MCHC was outside 
the reportable range 
(24.0-39.5 g/dL). 
Evaluate the patient’s condition; 
if a very high or low PLT value is 
not expected, rerun the sample 
WI 4 
Internal QA 
failure; 
qualiBeads® 
not recovered 
HGB, WBC, LYM, 
MONO, NEU, EOS, 
BASO, %LYM, 
%MONO, %NEU, 
%EOS, %BASO – 
no results reported 
(a) 
The analyzer did not 
recover the expected 
number of qualiBeads® 
(the internal quality 
assurance) 
Rerun the sample 
1 - Type of message: (a) instrument message, (b) sample message. Iraqi Journal of Veterinary Sciences, Vol. 27, No. 1, 2013 (1-7) 
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Table 6: Frequency of occurrence (%) of the alarm codes in the CBCs obtained from Lasercyte® in all patients and in patients 
subdivided by different blood disorders. 
 
Alarm code  All  cases  Lymphoma cases  Leukemia cases Miscellaneous blood disorders
DB 1/2  16.5  19.1 13.5 0.0
DB 1/3  12.4  15.7 6.4 0.0
DB 1-5  1.0  1.4 0.0 0.0
DB 3/4  0.6  0.0 2.6 0.0
DB 7  3.9  2.9 7.7 0.0
DB 10  2.3  1.9 3.8 0.0
HI 1  20.3  19.5 7.7 83.3
PB 1  4.1  0.0 16.0 0.0
RB 1  5.1  0.0 19.9 0.0
RB 3  1.6  0.0 6.4 0.0
RB 9  29.3  38.1 8.3 16.7
WB 1  1.9  0.0 7.7 0.0
WI 4  1.0  1.4 0.0 0.0
 
The value of RETIC was acceptable and RETIC % was 
fair, there was no improvement in these values, even when 
alarm codes were considered. When patients were analysed 
according to disorder, the (r) was optimal for MBD cases, 
acceptable for ML cases and acceptable or inadequate (for 
RETIC and % RETIC, respectively) for LEUK cases. It 
should be noted that in the LEUK cases, a severe disorder 
involving RBC was also occurring. 
According to previous papers (5,16), the WBC 
evaluation was optimal. In the differential WBC counts, the 
value of NEU and LYM was optimal if the alarm codes 
were considered. The (r) for the different disorders was 
optimal for ML, fair for LEUK cases and acceptable in the 
MBD cases. It is well established that NEU and LYMP 
make up a large proportion of the canine WBC population 
and LaserCyte® is able to characterize them, even in very 
severe blood disorders. 
The concordance for MONO was acceptable if the 
alarm codes were not considered and fair if they were. 
Considering both the nature of the disorder and the alarm 
codes, the (r) was acceptable for ML and LEUK patients 
and optimal for MBD cases. This data reflects the very 
severe derangements in ML and LEUK patients, this is 
especially true for the WBC differential counts. In addition, 
a previous investigation has already reported some 
difficulties in correctly identifying MONO using 
LaserCyte® (17). 
The EOS value was inadequate in all cases even when 
the alarm was considered. The lack of concordance for EOS 
between LaserCyte® and manual differential count has 
been reported previously (17). 
The analysis of PLT produced optimal consistency, 
except for LEUK patients. 
The last parameter to be considered was MPV, 
concordance was only acceptable when the alarm codes 
were disregarded. This was likely due to the way in which 
the impedance instrument measures mean PLT size, it is 
unable to detect small PLT aggregates.  
The frequency of occurrence of the several alarm codes 
from LaserCyte® was reported and related to the above 
results for each CBC parameter. The alarm code most 
represented was RB 9, which is “MCHC out of reportable 
range”, and indeed MCHC concordance was inadequate in 
all comparisons undertaken. The other, frequently occurring 
alarm code was related to MCHC, HI 1 “HGB sheath 
timing”. Other two commonly noted alarm codes (DB 1/2 
and DB 1/3) indicated that the LaserCyte® was unable to 
assess WBC morphology correctly because of difficulties in 
separating LYM from MONO and MONO from NEU 
respectively. In the LEUK patients, the PB 1 alarm code 
(“PLT out of reportable range”) had a frequency in 
comparison to the other two disorders, probably because the 
LEUK patients included a case of essential thrombocytemia. 
In conclusion, LaserCyte® appears to be a cell counter 
able to produce reliable results even during severe 
oncohematological disorders. If LaserCyte® is displaying 
alarm codes, these should always be taken into 
consideration as should the offered explanation and 
troubleshooting advice. Most of these recommendations 
include evaluation of the patient’s condition and 
examination of a stained blood smear. Of course this 
reiterates that blood disorders require careful investigation 
that usually involves examination of the blood smear. The 
only parameters that was unreliable, even following 
consideration of the alarm codes, is the EOS count, this 
finding has already reported in previous papers. 
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